THE CHALLENGE

Only 8% of drugs showing preclinical efficacy progress beyond Phase III oncology trials

Oncology drug development is notoriously ineffective, slow, and expensive due to the poor translatability of conventionally used models. 2D Cancer cells lack the complexity required for understanding cancer behavior in vivo, and animal models have fundamental species differences that limit their application for understanding human tumor biology. While patient-derived xenografts (PDX) are capable of replicating patient tumor antigens, they can only be stably established for advanced tumors and lack human immune components. Prioritizing models that retain patient tumor antigens is crucial for better understanding cancer and developing effective treatments.

OUR SOLUTION

Patient-derived tumor organoids across the continuum of oncology drug development

Patient-derived organoids are mini-organs derived directly from patient tumor biopsies. They are clinically relevant as they faithfully recapitulate the phenotypic and genotypic features of patient tumors, including key driver mutations and patient tumor antigens, and are genetically stable across long-term passages. They can also be co-cultured with human immune cells and stromal cells, making them highly modular to study the impact of multiple cellular and molecular factors on cancer progression and behavior. This model is advantageous for evaluating on-target off-site toxicities, a common concern in cancer research, as organoids can be generated from both healthy and tumor tissues.

PDO Screen

Fast and cost-effective screening on a preset panel of tumor organoids

PDO Screen is built upon the recent success of our organoid screening platform which led to the first oncology agent to be approved for clinical trials within 5 years of development. Select from a pre-set panel of patient-derived organoid models among the available tissue types for a fast, cost-efficient, and patient-relevant evaluation of your agent efficacy.

enrol now

PDO Co-cultures

Organoid-based immune cell co-culture platform

The development of successful oncology agents requires evaluating a drug’s impact on the epithelium as well as the immune and stromal cells. Modeling these intricate interactions in vivo often compromises scalability and cost, posing a hurdle in preclinical drug development. We offer unique organoid co-culture systems with various immune cells like autologous and allogeneic T cells, macrophages, neutrophils, NK cells, and fibroblasts. This allows for a deeper understanding of drug responses and paves the way for the development of next-generation cancer immunotherapies.

talk to an expert

Explore the science behind

CASE STUDY

Drug discovery to clinical trials in five years

download now

FACTSHEET

Tumor organoids for cancer research

download now

WHITE PAPER

Accelerating oncology drug discovery with HUB Organoids

view publication

Book your screen

Share your screening parameters with us. Our experts will get in touch with you shortly.
X

Have any questions?

contact us